ERBB2 and breast carcinoma: While our analysis provides a detailed examination of permissive cardiotoxicity in HER2-positive breast cancer patients treated with Trastuzumab, it is limited by the heterogeneity of the included studies and its primary focus on short-term outcomes, thereby restricting the generalizability of findings to long-term cardiotoxic effects.